Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Vaccinex Inc (VCNX)

Vaccinex Inc (VCNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vaccinex Reports 2025 Annual Financial Results GlobeNewswire - Wed Apr 29, 7:05PM CDT

ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s...

VCNX : 1.1000 (+8.91%)
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease GlobeNewswire - Tue Dec 23, 2025

ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting...

VCNX : 1.1000 (+8.91%)
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting GlobeNewswire - Tue May 27, 2025

VCNX : 1.1000 (+8.91%)
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) GlobeNewswire - Mon Apr 21, 2025

VCNX : 1.1000 (+8.91%)
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market GlobeNewswire - Fri Mar 7, 2025

VCNX : 1.1000 (+8.91%)
Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards Quiver Quantitative, Inc. - Tue Dec 17, 2024

Vaccinex announces Nasdaq delisting due to non-compliance with equity standards; trading shifts to OTC Markets.Quiver AI SummaryVaccinex, Inc., a clinical-stage biotechnology company focused on treating...

VCNX : 1.1000 (+8.91%)
Vaccinex, Inc. Reports Q3 Financial Results and Advances Alzheimer’s Development While Exploring Partnership Opportunities Quiver Quantitative, Inc. - Mon Nov 18, 2024

Vaccinex reports promising Alzheimer’s treatment results, financial updates, and plans for partnerships to enhance development.Quiver AI SummaryVaccinex, Inc. has reported its financial results for the...

VCNX : 1.1000 (+8.91%)
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire - Mon Nov 18, 2024

VCNX : 1.1000 (+8.91%)
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC GlobeNewswire - Thu Nov 7, 2024

VCNX : 1.1000 (+8.91%)
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting GlobeNewswire - Tue Nov 5, 2024

VCNX : 1.1000 (+8.91%)

Barchart Exclusives

Microsoft Stock Is an AI Bargain That Investors Are Missing Barchart - Sun May 17, 2:00PM CDT
Microsoft trades at a more attractive valuation relative to peers like Alphabet and Amazon. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.